Specialized in Intellectual Property & Portfolio Management for pharma, API, Devices and Specialty chemicals Mr. Bhar leveraged filing a number of NCE-1/F2F US generics

He has been engaged in developing many small molecules, recombinant gene product or bio-mimic APIs and complex generic products.

Product selection, Portfolio development and strategies, ANDA litigation, IP due diligence, Technology assessment, Client evaluation and Business development are the major

strengths of Mr. Bhar